195 related articles for article (PubMed ID: 36634606)
21. Neoplastic Myelopathies.
Wu J; Ranjan S
Continuum (Minneap Minn); 2018 Apr; 24(2, Spinal Cord Disorders):474-496. PubMed ID: 29613896
[TBL] [Abstract][Full Text] [Related]
22. Current Considerations in the Treatment of Grade 3 Gliomas.
Jo J; Schiff D
Curr Treat Options Oncol; 2022 Sep; 23(9):1219-1232. PubMed ID: 35913658
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
24. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
Daly MB; Pilarski R; Yurgelun MB; Berry MP; Buys SS; Dickson P; Domchek SM; Elkhanany A; Friedman S; Garber JE; Goggins M; Hutton ML; Khan S; Klein C; Kohlmann W; Kurian AW; Laronga C; Litton JK; Mak JS; Menendez CS; Merajver SD; Norquist BS; Offit K; Pal T; Pederson HJ; Reiser G; Shannon KM; Visvanathan K; Weitzel JN; Wick MJ; Wisinski KB; Dwyer MA; Darlow SD
J Natl Compr Canc Netw; 2020 Apr; 18(4):380-391. PubMed ID: 32259785
[TBL] [Abstract][Full Text] [Related]
25. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
[TBL] [Abstract][Full Text] [Related]
26. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
Schaeffer E; Srinivas S; Antonarakis ES; Armstrong AJ; Bekelman JE; Cheng H; D'Amico AV; Davis BJ; Desai N; Dorff T; Eastham JA; Farrington TA; Gao X; Horwitz EM; Ippolito JE; Kuettel MR; Lang JM; McKay R; McKenney J; Netto G; Penson DF; Pow-Sang JM; Reiter R; Richey S; Roach Iii M; Rosenfeld S; Shabsigh A; Spratt DE; Teply BA; Tward J; Shead DA; Freedman-Cass DA
J Natl Compr Canc Netw; 2021 Feb; 19(2):134-143. PubMed ID: 33545689
[TBL] [Abstract][Full Text] [Related]
27. Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
Jo J; van den Bent MJ; Nabors B; Wen PY; Schiff D
Neuro Oncol; 2022 Jul; 24(7):1035-1047. PubMed ID: 35137214
[TBL] [Abstract][Full Text] [Related]
28. Adult Diffuse Astrocytic and Oligodendroglial Tumors.
Gestrich CK; Couce ME; Cohen ML
Neurosurgery; 2021 Oct; 89(5):737-749. PubMed ID: 33611566
[TBL] [Abstract][Full Text] [Related]
29. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.
Nabors LB; Portnow J; Ammirati M; Brem H; Brown P; Butowski N; Chamberlain MC; DeAngelis LM; Fenstermaker RA; Friedman A; Gilbert MR; Hattangadi-Gluth J; Hesser D; Holdhoff M; Junck L; Lawson R; Loeffler JS; Moots PL; Mrugala MM; Newton HB; Raizer JJ; Recht L; Shonka N; Shrieve DC; Sills AK; Swinnen LJ; Tran D; Tran N; Vrionis FD; Wen PY; McMillian NR; Ho M
J Natl Compr Canc Netw; 2014 Nov; 12(11):1517-23. PubMed ID: 25361798
[TBL] [Abstract][Full Text] [Related]
30. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R; Dehais C; Maurage CA; Alentorn A; Carpentier C; Colin C; Ducray F; Escande F; Idbaih A; Kamoun A; Marie Y; Mokhtari K; Tabouret E; Trabelsi N; Uro-Coste E; Delattre JY; Figarella-Branger D;
Neuro Oncol; 2019 Dec; 21(12):1519-1528. PubMed ID: 31832685
[TBL] [Abstract][Full Text] [Related]
31. NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023.
Bevers TB; Niell BL; Baker JL; Bennett DL; Bonaccio E; Camp MS; Chikarmane S; Conant EF; Eghtedari M; Flanagan MR; Hawley J; Helvie M; Hodgkiss L; Hoyt TL; Ivanovich J; Jochelson MS; Kulkarni S; Lancaster RB; Mauer C; Maxwell J; Patel BK; Pearlman M; Philpotts L; Plecha D; Plichta JK; Shakeri S; Smith ML; Streibert CL; Strigel RM; Tumyan L; Winkler NS; Wolverton DE; Bergman MA; Kumar R; Stehman K
J Natl Compr Canc Netw; 2023 Sep; 21(9):900-909. PubMed ID: 37673117
[TBL] [Abstract][Full Text] [Related]
32. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update.
Whitfield BT; Huse JT
Brain Pathol; 2022 Jul; 32(4):e13062. PubMed ID: 35289001
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of molecular analysis in diffuse glioma stratification.
Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Fujioka Y; Takigawa K; Funakoshi Y; Suzuki SO; Iwaki T
Brain Tumor Pathol; 2021 Jul; 38(3):210-217. PubMed ID: 34268651
[TBL] [Abstract][Full Text] [Related]
34. Central Nervous System Metastases.
Nieblas-Bedolla E; Zuccato J; Kluger H; Zadeh G; Brastianos PK
Hematol Oncol Clin North Am; 2022 Feb; 36(1):161-188. PubMed ID: 34711458
[TBL] [Abstract][Full Text] [Related]
35. Nogo-a expression in glial CNS tumors: a tool to differentiate between oligodendrogliomas and other gliomas?
Kuhlmann T; Gutenberg A; Schulten HJ; Paulus W; Rohde V; Bruck W
Am J Surg Pathol; 2008 Oct; 32(10):1444-53. PubMed ID: 18685489
[TBL] [Abstract][Full Text] [Related]
36. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.
Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H
J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111
[TBL] [Abstract][Full Text] [Related]
37. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.
Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M
J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432
[TBL] [Abstract][Full Text] [Related]
38. Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas.
Liu Y; Chen H; Li G; Zhang J; Yao K; Wu C; Li S; Qiu X
Cancer Biol Med; 2022 Nov; 19(10):1477-86. PubMed ID: 36350001
[TBL] [Abstract][Full Text] [Related]
39. Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.
Wood MD; Halfpenny AM; Moore SR
Diagn Pathol; 2019 Apr; 14(1):29. PubMed ID: 30967140
[TBL] [Abstract][Full Text] [Related]
40. Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.
Lasocki A; Buckland ME; Drummond KJ; Wei H; Xie J; Christie M; Neal A; Gaillard F
Neuroradiology; 2022 Dec; 64(12):2295-2305. PubMed ID: 35606654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
